nivolumab,ipilimumab
ono Pharmaceuticals,bms
['checkmate 358', 'bristol']
at the ongoing 2022 conference, in the mini oral session, presented positive results from the phase i/ii (checkmate 358) trial. for more detailed analysis, visit: #esmo2022 #esmo #esmo22 #breakthroughs #abstracts #oncology 
#DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the healthcare industry